Two Onc Docs ASCO 2025 Plenary - MATTERHORN
Jul 7, 2025
Delve into the groundbreaking MATTERHORN trial, where the synergy of durvalumab and the FLOT regimen offers new hope for resectable gastric cancer. Learn about the exciting results presented at the ASCO 2025 plenary session and how these findings could reshape future treatments. The discussion also explores current standards of care and the potential impact pending further research and FDA approval. This session highlights the innovative intersection of immunotherapy and conventional approaches in oncology.
AI Snips
Chapters
Transcript
Episode notes
FLOT Is The Perioperative Standard
- FLOT (perioperative 4 cycles pre and 4 cycles post) became the standard after FLOT4 showed OS improved to 50 vs 35 months over ECF/ECX.
- This established perioperative FLOT as the backbone for trials adding immunotherapy in resectable gastric/GEJ cancer.
MATTERHORN Trial Design
- MATTERHORN randomized 1:1 durvalumab 1500 mg vs placebo every 4 weeks added to perioperative FLOT with a year of maintenance IO.
- The primary endpoint was event-free survival with secondary endpoints including overall survival and pathologic complete response.
Durvalumab Improved Event-Free Survival
- MATTERHORN met its primary EFS endpoint with hazard ratio 0.71 and a 29% relative risk reduction versus placebo.
- Two-year EFS was 67.4% with durvalumab vs 58.5% with placebo and median EFS was not reached vs 32.8 months.